LifeMD is trading at $3.28 (-10.87%) in pre-market after reporting second-quarter revenue of $47.3 million and a $0.16 loss per share.
- The company lowered its full-year 2026 revenue and adjusted EBITDA guidance, citing near-term profitability pressure from its transition to branded GLP-1 therapies.
- While active subscriber growth remained strong, investors are reacting negatively to the guidance reset and anticipated margin compression.
- The price action is company-specific, as broader market indices are trading only modestly mixed before the opening bell.